S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Baker Bros Advisors/Q2 2026

Baker Bros Advisors

Period: Q2 2026 · Filed: 2026-08-14
View on SEC EDGAR
AUM
$19.96B
Total portfolio value
Positions
84
Reported securities
Top Holding
INCY
17.5% $3.49B
QoQ Changes
+8 / -8
new · exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings — not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares — not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with ≥$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2026-08-14) shown is the underlying stock price movement — not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
INCYIncyte Corporation$3.49B17.48%$113.36$120.16+6.0%
17.5%
ONCBeOne Medicines Ltd.$2.51B12.57%$284.97$347.48+21.9%
12.6%
RVMDRevolution Medicines, Inc.$2.14B10.74%$187.28$203.71+8.8%
10.7%
MDGLMadrigal Pharmaceuticals, Inc.$1.15B5.77%$536.95$507.56-5.5%
5.8%
ACADACADIA Pharmaceuticals Inc.$1.09B5.44%$25.30$28.24+11.6%
5.4%
KYMRKymera Therapeutics, Inc.$992.7M4.97%$114.67$117.39+2.4%
5.0%
INSMInsmed Incorporated$937.8M4.70%$106.62$123.74+16.1%
4.7%
CELCCelcuity Inc.$828.1M4.15%$104.62$92.00-12.1%
4.2%
KODKodiak Sciences Inc.$776.0M3.89%$38.96$41.35+6.1%
3.9%
RYTMRhythm Pharmaceuticals, Inc.$622.3M3.12%$111.03$115.48+4.0%
3.1%
PRAXPraxis Precision Medicines, Inc.$587.0M2.94%$334.79$366.81+9.6%
2.9%
ALKSAlkermes plc$524.6M2.63%$52.40$49.06-6.4%
2.6%
SMMTSummit Therapeutics Inc.$477.7M2.39%$14.57$13.35-8.4%
2.4%
GRALGRAIL, Inc.$275.0M1.38%$68.27$67.87-0.6%
1.4%
ABCLAbCellera Biologics Inc.$259.1M1.30%$7.85$11.38+45.0%
1.3%
IMVTImmunovant, Inc.$209.4M1.05%$38.53$41.82+8.5%
1.1%
IDYAIDEAYA Biosciences, Inc.$186.7M0.94%$37.27$36.30-2.6%
0.9%
KNSAKiniksa Pharmaceuticals International, plc$181.3M0.91%$63.95$76.75+20.0%
0.9%
ROIVRoivant Sciences Ltd.$166.9M0.84%$35.39$36.20+2.3%
0.8%
ARWRArrowhead Pharmaceuticals, Inc.$162.4M0.81%$81.51$86.64+6.3%
0.8%
IONSIonis Pharmaceuticals, Inc.$162.4M0.81%$79.29$57.24-27.8%
0.8%
EWTXEdgewise Therapeutics, Inc.$150.4M0.75%$40.63$44.17+8.7%
0.8%
REPLReplimune Group, Inc.$122.3M0.61%$11.07$14.97+35.2%
0.6%
NRIXNurix Therapeutics, Inc.$113.0M0.57%$24.26$27.05+11.5%
0.6%
STOKStoke Therapeutics, Inc.$109.2M0.55%$32.72$31.27-4.4%
0.6%
GLUEMonte Rosa Therapeutics, Inc.$105.2M0.53%$24.20$15.50-36.0%
0.5%
IMTXImmatics N.V.$96.3M0.48%$10.13$9.44-6.8%
0.5%
DNLIDenali Therapeutics Inc.$96.0M0.48%$25.72$24.40-5.1%
0.5%
CRNXCrinetics Pharmaceuticals, Inc.$88.0M0.44%$37.42$84.70+126.3%
0.4%
DNTHDianthus Therapeutics, Inc.$83.1M0.42%$97.48$115.96+19.0%
0.4%

Quarter-on-Quarter Activity

Q2 2026 vs. Q1 2026

New Positions (8)

TickerIssuerNotional
SNSEFaeth Therapeutics, Inc.$32.2M
CYTKCytokinetics, Incorporated$18.0M
NTLAIntellia Therapeutics, Inc.$15.7M
Parabilis Medicines, Inc.$13.7M
AVLNAvalyn Pharma Inc.$11.5M
TNGXTango Therapeutics, Inc.$10.4M
AVTXAvalo Therapeutics, Inc.$10.2M
IMNMImmunome, Inc.$1.2M

Exited Positions (8)

TickerIssuerNotional
ABVXAbivax S.A.$97.5M
SYRESpyre Therapeutics, Inc.$50.4M
CNTACentessa Pharmaceuticals plc$26.6M
IMCRImmunocore Holdings plc$22.1M
CTNMContineum Therapeutics, Inc.$18.6M
ARGXargenx SE$18.4M
CMPSCOMPASS Pathways plc$13.0M
PHVSPharvaris N.V.$10.6M

Increased (8)

TickerIssuerNotionalShares ΔSince Filing
VSTMVerastem, Inc.$6.5M+327.4%
RLAYRelay Therapeutics, Inc.$41.4M+143.7%
RCUSArcus Biosciences, Inc.$17.1M+103.3%
CLDXCelldex Therapeutics, Inc.$22.9M+77.7%
IDYAIDEAYA Biosciences, Inc.$55.2M+26.9%-2.6%
VRDNViridian Therapeutics, Inc.$5.2M+20.9%
RVMDRevolution Medicines, Inc.$1.21B+19.8%+8.8%
INSMInsmed Incorporated$-275.7M+18.5%+16.1%

Trimmed (7)

TickerIssuerNotionalShares ΔSince Filing
EWTXEdgewise Therapeutics, Inc.$-56.7M-43.7%+8.7%
CERSCerus Corporation$0.5M-36.1%
JBIOJade Biosciences, Inc.$4.3M-25.0%
IMTXImmatics N.V.$-11.1M-12.9%-6.8%
SMMTSummit Therapeutics Inc.$-212.3M-9.9%-8.4%
ROIVRoivant Sciences Ltd.$32.1M-3.1%+2.3%
IMVTImmunovant, Inc.$73.8M-0.4%+8.5%
Back to Hedge Funds